Approval · Notice of Compliance 27091 · 2021

WEGOVY: Notice of Compliance 27091

Issued November 23, 2021

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 27091
Date: November 23, 2021
Company: Novo Nordisk Canada IncMississauga, Ontario, Canada
Product type: Biologic
Submission: New Drug Submission (NDS)
Submission class: Other

Products in this notice

Brand	DIN	Status today
WEGOVY	02522551	Approved
WEGOVY	02522578	Approved
WEGOVY	02522586	Approved
WEGOVY	02522594	Approved
WEGOVY	02522608	Approved

Medicinal ingredients

SEMAGLUTIDE 0.25 MG per 0.5ML
SEMAGLUTIDE 0.5 MG per 0.5ML
SEMAGLUTIDE 1 MG per 0.5ML
SEMAGLUTIDE 1.7 MG per 0.75ML
SEMAGLUTIDE 2.4 MG per 0.75ML